Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GemCaN: Nivolumab + Cabiralizumab + Gemcitabine in Advanced Pancreatic Cancer
NCT03697564Phase 2Completed
- Start
- Oct 2019
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cabiralizumab in pancreatic cancer (PC) (2 arms). Primary endpoint: Progression Free Survival at 6 months. Started Oct 2019; status: completed.
02
Drugs
cabiralizumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03697564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03697564.